The Procedures

Before a medical device can be implanted in a human patient, regulators require evidence that it is biocompatible, mechanically sound, and safe over its intended lifespan. For implantable devices — joint replacements, heart valves, spinal fusion hardware, dental implants, pacemakers — that evidence often comes from chronic implant studies in dogs. These studies place the actual device (or a prototype) inside a living animal, monitor it for weeks to months, then sacrifice the animal to examine the tissue response at a microscopic level.

Unlike pharmaceutical toxicology, which tests chemical compounds, device testing evaluates physical objects: their mechanical interaction with bone and tissue, the body's inflammatory and immune response to implant materials, and whether the device degrades, migrates, or fails under real biological conditions.

The FDA classifies medical devices into three risk tiers. The higher the risk class, the more likely animal studies are required before human trials can begin.

Dogs are not chosen arbitrarily. They are selected because specific aspects of their anatomy create a closer parallel to the human implant environment than smaller species can provide.

A typical device implant study follows a structured surgical protocol. While details vary by device category, the core sequence is consistent across orthopedic, cardiovascular, and dental studies.

After implant surgery, dogs enter an extended monitoring phase. This is the core of device testing — the period during which the body's response to the foreign material is assessed over time.

Device testing studies fall into two endpoint categories, and the distinction matters for understanding what happens to the animals.

The global medical device market exceeds $200 billion annually and is growing at approximately 5% per year. Several trends are increasing, not decreasing, the demand for animal testing of devices.

Novel biomaterials — resorbable polymers, drug-eluting coatings, 3D-printed porous metals, bioactive ceramics — each require fresh biocompatibility data because prior test results for one material cannot be extrapolated to another. Every new material-device combination is, from a regulatory perspective, a new product requiring its own preclinical package.

Combination products (devices that incorporate drugs or biologics, such as drug-eluting stents or antibiotic-loaded bone cements) face requirements from both the device and drug regulatory pathways, potentially doubling the animal testing burden.

Global market expansion means that manufacturers seeking approval in the U.S., EU, Japan, and China may need to satisfy overlapping but non-identical regulatory frameworks. While harmonization efforts (IMDRF) aim to reduce duplication, in practice many sponsors conduct separate or supplementary animal studies for different markets.

Device testing in dogs occupies a peculiar blind spot. Public debate about animal testing focuses overwhelmingly on pharmaceutical toxicology. But the device pipeline is structurally different in ways that reduce its visibility.

Most device testing is conducted by contract research organizations (CROs) under GLP conditions, with results submitted directly to regulators in proprietary premarket approval applications. The data rarely appears in peer-reviewed journals. Device companies are not required to publish their preclinical results, and competitive pressures discourage voluntary disclosure.

The result is that a growing segment of dog use in research — driven by a rapidly expanding global device market and increasingly complex implant technologies — is essentially invisible to public scrutiny. This matters because device testing involves some of the most invasive procedures dogs experience in laboratories: major surgery, chronic implantation, extended monitoring under restricted conditions, and terminal sacrifice for tissue harvest.